書籍詳細

[1] 抗菌薬療法の基本原則

P.24 掲載の参考文献

• 1) World Health Organization:WHO global strategy for containment of antimicrobial resistance. http://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_DRS_2001_2_EN/en/

• 2) Centers for Disease Control and Prevention:Campaign to prevent antimicrobial resistance. http://www.cdc.gov/drugresistance/healthcare/patients. htm, 2002.

• 3) Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL:Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Care Med 2001, 163:1730-1754.

• 4) Nicolle LE, Bentley D, Garibaldi R, Neuhaus E, Smith P, SHEA Long-Term-Care Committee:Antimicrobial use in long-term-care facilities. Infect Control Hosp Epidemiol 1996, 17:119- 128.

• 5) World Health Organization:Prevention of hospital-acquired infections, a practical guide, 2nd ed. http://www.who.int/csr/resources/publications/drugresist/WHO_CDS_CSR_EPH_2002_12/en/

• 6) Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ:Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31:347-382.
  pubmed

• 7) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人市中肺炎診療ガイドライン, 日本呼吸器学会, 東京, 2005.

• 8) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人院内肺炎診療の基本的考え方. 日本呼吸器学会, 東京, 2002.

• 9) Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS:2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.

• 10) Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE:Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1272.

• 11) 日本感染症学会, 日本化学療法学会:抗菌薬使用の手引き. 協和企画, 東京, 2001.

• 12) American Thoracic Society, Infectious Diseases Society of America:Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.

• 13) Moellering RC Jr, Eliopoulos GM:Principles of anti-infective therapy. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p242-253.

• 14) Archer GL, Polk RE:Treatment and prophylaxis of bacterial infections. Harrison's principles of internal medicine, 15th ed. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds, New York:McGraw-Hill, 2001, p867-882.

• 15) Reese RE, Betts RF:Principles of antibiotic use. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p969-988.

• 16) 堀井俊伸:ここがポイント! 感染症診療と感染対策のための基本手技. 文光堂, 東京, 2004.

• 17) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 18) Eliopoulos GM, Moellering RC Jr:Antimicrobial combinations. Antibiotics in Laboratory Medicine, 4th ed. Lorian V, ed. Baltimore:Williams & Wilkins, 1996, p330-390.

• 19) 堀井俊伸, 村松英彰:生化学的検査/バンコマイシン, アルベカシン, テイコプラニン. 検査項辞典. 医歯薬出版, 東京, 2003, p489-491.

• 20) Nichols RL:Surgical antibiotic prophylaxis. Med Clin North Am 1995, 79:509-522.
  pubmed

• 21) Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, The Hospital Infection Control Practices Advisory Committee:Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999, 20:247-278.

• 22) 国立大学医学部附属病院感染対策協議会:手術部位感染防止対策. 病院感染対策ガイドライン, 平成15年8月版, 2003, p69-76.

• 23) Sobel JD, Kaye D:Urinary tract infections. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Doloin R, eds. New York:Elsevier Churchill Livingstone, 2004, p875-905.

• 24) 国立大学医学部附属病院感染対策協議会:尿路感染防止, 尿道留置カテーテル管理. 病院感染対策ガイドライン. 平成15年8月版. 2003, p52-58.

• 25) 国立大学医学部附属病院感染対策協議会:人工呼吸器関連肺炎防止. 病院感染対策ガイドライン. 平成15年8月版. 2003, p59-68.

• 26) Kluytmans JA, Mouton JW, VandenBergh MF, Manders MJ, Maat AP, Wagenvoort JH, Michel MF, Verbrugh HA:Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996, 17:780-785.
  pubmed

• 27) Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Kobayashi S, Sato A, Sugita R, Nagatake T:Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2001, 39:3775-3777.
  pubmed

• 28) Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA, Mupirocin and the Risk of Staphylococcus aureus Study Team:Intranasal mupirocin to prevent postoperative Staphylococcus aureus infctions. N Engl J Med 2002, 346:1871-1877.

• 29) 堀井俊伸, 斉藤 崇, 尾澤法代・他:学会企画のまとめ・技師の求める患者情報, 医師の求める検査情報とは -第14回日本臨床微生物学会総会ワークショップ「感染症症例ツアー」企画からの考察-. 日臨微誌 2003, 13:31-58.

• 30) Craig WA:Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
  pubmed

• 31) Craig WA:Re-evaluating current antibiotic therapy. Respir Med 2001, 95 (Suppl A):S12-S19.
  pubmed

• 32) Jacobs MR:Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001, 7:589-596,
  pubmed

• 33) Craig WA:Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. ed. Expanding indications for the new macrolides, azalides, and streptogramins. Zimer SH, ed. New York:Marcel Dekker, 1997, p27-38.

• 34) Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ:Clinical pharmacodynamics of linezolid in seriously ill patients in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.

• 35) Jacobs RA, Guglielmo BJ:Anti-infective chemotherapeutic and antibiotic agents. Current medical diagnosis & treatment 2003, 42nd ed. Mandell GL, Bennett JE, Doloin R, eds. New York:Lange Medical Books/McGraw-Hill, 2003, p1495-1535.

• 36) American Academy of Pediatrics Committee on Drugs:Transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108:776-789.

[2] 検査診断法の抗菌薬療法への活用

P.64 掲載の参考文献

• 1) 堀井俊伸, 斉藤 崇, 尾澤法代, 他:学会企画のまとめ・技師の求める患者情報, 医師の求める検査情報とは -第14回日本臨床微生物学会総会ワークショップ「感染症症例ツアー」企画からの考察-. 日臨微誌 2003, 13:31-58.

• 2) Miller JM, Holmes HT, Krisher K:General principles of specimen collection and handling. Manual of clinical microbiology, 8th ed. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Washington DC:American Society for Microbiology, 2003, p55-66.

• 3) Gill VE, Fedorko DP, Witebsky FG:The clinician and the microbiology laboratory. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p203-241.

• 4) Saito T, Senda K, Takakura S, Fuj ihara N, Kudo T, Iinuma Y, Fujita N, Komori T, Baba N, Horii T, Matsuoka K, Tanimoto M, Ichiyama S:Anaerobic bacteremia:the yield of positive anaerobic blood cultures:patient characteristics and potential risk factors. Clin Chem Lab Med 2003, 41:293-297.

• 5) 堀井俊伸:ここがポイント! 感染症診療と感染対策のための基本手技. 文光堂, 東京, 2004.

• 6) Bisno AL:Pharyngitis. Principles and practice of infectious diseases. Mandell GL, Bennett JE, Dolin R, eds, 6th ed. New York:Elsevier Churchill Livingstone, 2004, p752-758.

• 7) Gwaltney JM Jr:Sinusitis. Principles and practice of infectious diseases. Mandell GL, Bennett JE, Dolin. R, eds, 6th ed. New York:Elsevier Churchill Livingstone, 2004, p203-241.

• 8) Granato PA:Pathogenic and indigenous microorganisms of humans. Manual of clinical microbiology, 8th ed. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Washington DC:American Society for Microbiology, 2003, p44-54.

• 9) 日本結核病学会抗酸菌検査法検討委員会:新結核菌検査指針 2000. 財団法人結核予防, 東京, 2000.

• 10) 国立大学医学部附属病院感染対策協議会:結核対策. 病院感染対策ガイドライン, 平成15年8月版. 2002, p22-35.

• 11) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 12) Ward T, Jones SR:Genitourinary tract infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p493-540.

• 13) Sobel JD, Kaye D:Urinary tract infections, Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p875-905.

• 14) Wilson ML, Gaido L:Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004, 38:1150-1158.
  pubmed

• 15) McCormack WM, Rein MF:Urethritis. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p 1347-1357.

• 16) Tunkel AR, Scheld WM:Acute meningitidis. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p1083-1126.

• 17) Baron EJ, Weinstein MP, Dunne WM Jr, Yagupsky P, Welch DF, Wilson DM:Blood cultures. Cumulative techniques and procedures in clinical microbiology(CUMITECH) 1C. Barton EJ, ed, Washington DC:American Society for Microbiology, 2005.

• 18) 金井 泉:穿刺・髄液検査. 臨床検査法提要(Kanai's Manual of Clinical Laboratory Medicine). 改訂第31版, 金原出版, 東京, 1998, p225-259.

• 19) National Committee for Clinical Laboratory Standards:Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Wayne:NCCLS, Approved Standard M7-A5, 2001.

• 20) 日本感染症学会・日本化学療法学会:抗菌薬使用の手引き. 協和企画, 東京, 2001.

• 21) 遠藤廣子:市中感染と耐性菌-急性気道感染症と中耳炎. 小児感染免疫 2003, 15:59-67.

• 22) Ishida T, Hashimoto T, Arita M, Ito I, Osawa M:Etiology of community-acquired pneumonia in hospitalized patients, a 3-year prospective study in Japan. Chest 1998, 114:1588-1593.
  pubmed

• 23) 森川嘉朗:化膿性髄膜炎の最近の治療. 小児感染免疫 2001, 13:177-187.

• 24) 伊藤真人, 古川 仭:保育園と耐性菌感染. 小児感染免疫 2003, 15:117-123.

• 25) 崔 信明, 高橋尚人, 仁志田博司:MRSA感染及びその対策に関する意識調査. 日児誌 2001, 105:1123-1125.

• 26) 紺野昌俊, 生方公子:改訂ペニシリン耐性肺炎球菌. 協和企画, 東京, 1999.

• 27) 吉田 勇, 木村美司, 東山伊佐夫, 杉森義一, 山野義則:各種抗菌薬に対する臨床分離株の感受性サーベイランス -2000年分離グラム陽性球菌および嫌気性菌に対する抗菌力-. 日化療会誌 2003, 51:179-208.

• 28) 吉田 勇, 杉森義一, 東山伊佐夫, 木村美司, 山野義則:各種抗菌薬に対する臨床分離株の感受性サーベイランス -2000年分離グラム陰性菌に対する抗菌力-. 日化療会誌 2003, 51:209-232.

• 29) Petersdorf RG, Beeson PB:Fever of unexplained origin:report on 100 cases. Medicine 1961, 40:1-30.
  pubmed

• 30) Knockaert DC, Duj ardin KS, Bobbaers HJ:Long-term follow-up of patients with undiagnosed fever of unknown origin. Arch Intern Med 1996, 156:618-620.

[3] 領域別にみた抗菌薬療法

P.76 掲載の参考文献

• 1) 斎藤 厚:敗血症. 抗菌薬使用の手引き. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2001, p43-49.

• 2) Dorman JN:Sepsis. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, penn RL, eds. philadelphia:Lippincott Williams & Wilkins, 2003, p 19-66.

• 3) Gilbert DG, Moellering RC Jr, Eliopoulos GM, Sande MA:サンフォード感染症治療ガイド 2005, 第35版. ライフサイエンス出版, 東京, 2005.

• 4) 堀井俊伸:ここがポイント! 感染症診療と感染対策のための基本手技. 文光堂, 東京, 2004.

• 5) Shimada J, Hayashi I, Inamatsu T, Ishida M, Iwai S, Kamidono S, Kurosawa H, Masaoka T, Matsumoto F, Monden M, Morii H, Nakashio S, Narita N, Sakai O, Toda G, Shimizu K, Ueda Y, Ohno T:Clinical trial of in-situ hybridization method for the rapid diagnosis of sepsis. J Infect Chemother 1999, 5:21-31.
  pubmed

• 6) Klastersky J:Febrile neutropenia. Curr Opin Oncol 1993, 5:625-632.
  pubmed

• 7) Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655.
  pubmed

• 8) Rodriguez-Gaspar M, Santolaria F, Jarque-Lopez A, Gonzalez-Reimers E, Milena A, de la Vega MJ, Rodriguez-Rodriguez E, Gomez-Sirvent JL:Prognostic value of cytokines in SIRS general medical patients. Cytokine 2001, 15:232-236.
  pubmed

• 9) Bochud PY, Calandra T:Pathogenesis of sepsis:new concepts and implications for future treatment. BMJ 2003, 326:262-266.
  pubmed

• 10) Carlet J:Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 1999, 13:483-494.
  pubmed

• 11) Brunkhorst FM, Eberhard OK, Brunkhorst R:Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999, 27:2172-2176.
  pubmed

• 12) Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J:Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001, 164:396-402.
  pubmed

• 13) Reese RE, Betts RF:Antibiotic Use:clindamycin. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p1077-1081.

• 14) O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA:Guidelines for the prevention of intravascular catheter-related infections. Morb Mort Wkly Rep 2002, 51(RR-10):1-29.

• 15) Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE:Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32:1249-1279.

• 16) Shanson DC:New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis J Antimicrob Chemother 1998, 42:392-396.

• 17) Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Fenieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro Jr:Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997, 277:1794-1801.

• 18) Strom BL, Abrutyn E, Berlin JA, Kinman JL, Feldman RS, Stolley PD, Levison ME, Korzeniowski OM, Kaye D:Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 1998, 129:761-769.
  pubmed

P.96 掲載の参考文献

• 1) Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL:Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001, 163:1730-1754.
  pubmed

• 2) Bartlet JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ:Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31:347-382.

• 3) Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C:Update of practice guidelines for the management of community-acquired pneumonia in immmunocompetent adults. Clin Infect Dis 2003, 37:1405-1433.

• 4) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人市中肺炎診療の基本的考え方. 日本呼吸器学会, 東京, 2000.

• 5) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人市中肺炎診療ガイドライン. 日本呼吸器学会, 東京, 2005.

• 6) Ishida T, Hashimoto T, Arita M, Ito I, Osawa M:Etiology of community-acquired pneumonia in hospitalized patients, a 3-year prospective study in Japan. Chest 1998, 114:1588-1593.
  pubmed

• 7) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005. 35th ed. Hyde park:Antimicrobial Therapy, 2005.

• 8) Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A:Etiology of community-acquired pneumonia:impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999, 160:397-405.
  pubmed

• 9) Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF:Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000, 30:520-529.
  pubmed

• 10) Maurin M, Raoult D:Q fever. Clin Microbiol Rev 1999, 12:518-553.
  pubmed

• 11) 田原研司, 板垣朝夫:鳥展示施設に関連したオウム病集団発生事例. 病原微生物検出情報 2002, 23:247-248.

• 12) American Thoracic Society:Infectious Diseases Society of America:Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.

• 13) Centers for Disease Control and prevention:Guideline for prevention of nosocomial pneumonia. Morb Mort Wkly Rep 1997, 46:1-79.

• 14) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人院内肺炎診療の基本的考え方. 日本呼吸器学会, 東京, 2002.

• 15) 深在性真菌症のガイドライン作成委員会:深在性真菌症の診断・治療ガイドライン, 医歯薬出版, 東京, 2003.

• 16) Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kem WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B;Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group:Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-15.

• 17) Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, Bartok A, Nioshi J, Abramson I, Coffinan J, et al:A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990, 323:1451-1457.

• 18) American Thoracic Society:Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994, 149:1359-1374.
  pubmed

• 19) 日本結核病学会治療委員会:「結核医療基準」の見直し. 結核 2002, 77:537-538.

• 20) Iseman MD:Treatment and implication of multidrugg-resistant tuberculosis for the 21st century. Chemotherapy 1999, 45(Suppl 2):34-40.

• 21) American Thoracic Society:Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997, 156:s1-s15.
  pubmed

• 22) 日本結核病学会非定型抗酸菌症対策委員会:肺非結核抗酸菌症診断に関する見解-2003年. 結核 2003, 78:569-572.

• 23) 二木芳人:呼吸器感染症-気道感染症. 抗菌薬使用のガイドライン(日本感染症学会, 日本化学療法学会編). 協和企画, 東京, 2005, p100-105.

• 24) Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H:Erythromycin and common cold in COPD. Chest 2001, 120:730-733

• 25) Tsang KW, Ho PI, Chan KN, lp MS, Lam WK, Ho CS, Yuen KY, Ooi GC, Amitani R, Tanaka E:A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.

• 26) Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M:Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
  pubmed

• 27) Tamaoki J, Isono K, Sakai N, Kanemura T, Komo K:Erythromycin inhibits CI secretion across canine tracheal epithelial cells. Eur Respir J 1992, 5:234-238.

• 28) Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Tanaka M, Kasama T, Kobayashi K, Nakajima J, Ito K:Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997, 156:266-271.
  pubmed

• 29) Tateda K, Comite R, Pechere JC, Kohler T, Yamaguchi K, van Delden C:Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001, 45:1930- 1933.

• 30) 小林宏行:びまん性汎細気管支炎に対するマクロライドの作用機序. 日化療会誌 1995, 43:96-101.

P.115 掲載の参考文献

• 1) Manatsathit S, Dupont HL, Farthing M, Kositchaiwat C, Leelakusolvong S, Ramakrishna BS, Sabra A, Speelman P, Surangsrirat S, Working Party of the Program Committ of the B angkok World Congress of Gastroenterology 2002:Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol 2002, 17(Suppl):S54-S71.

• 2) Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hemessy T, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK, Infectious Diseases Society of America:Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32:331-351.

• 3) DuPont HL:Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol 1997, 92:1962-1975.
  pubmed

• 4) Bauer TM, Lalvani A, Fehrenbach J, Steffen I, Aponte JJ, Segovia R, Vila J, Philippczik G, Steinbruckner B, Frei R, Bowler I, Kist M:Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA, 285:313-319.
  pubmed

• 5) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde park:Antimicrobial Therapy, 2005.

• 6) DuPont HL:Quinolones in Salmonella typhi i fection. Drugs 1993, 45(Suppl 3):119-124.

• 7) Lesser CF, Miller SI:サルモネラ症. ハリソン内科学(日本語版), 原著第15版. メディカル・サイエンス・インターナショナル, 東京, 2003, 1004-1009.

• 8) Musher DM, Rubenstein AD:Permanent carriers of nontyphosa salmonellae. Arch Intern Med 1973, 132:869-872.
  pubmed

• 9) 仁科雅良:細菌性食中毒. 治療 2005, 77:392-396.

• 10) Adachi JA, Ostrosky-Zeichner L:Empirical antimicrobial therapy for traveler's diarrhea. Clin Infect Dis 2000, 31:1079-1083.

• 11) Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM:Escherichia coli O157:H7 diarrhea in the United States:clinical and epidemiologic features. Ann Intern Med 1997, 126:505-513.
  pubmed

• 12) Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI:The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coti O157:H7 infections. N Engl J Med 2000, 342:1930-1936.

• 13) Safdar N, Said A, Gangnon RE, Maki DG:Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis:ameta-analysis. JAMA 2002, 288:996-1001.

• 14) Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Terata K:Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999, 52:357-362.

• 15) Horii T, Kimura T, Sato K, Shibayama K, Ohta M:Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother 1999, 43:789-793.
  pubmed

• 16) Fille M, Larcher C, Dierich MP, Allerberger F:Evaluation of four methods for detection of Clostridium defficile or C defficile toxin:cytotoxin assay, culture, latex agglutination, and a new rapid immunoassay(C. defficile toxin A test). J Gastroenterol 1998, 36:143-149.

• 17) Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr:Clostridium defficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, 16:459-477.

• 18) Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr:Prospective randomised trial of metronidazole versus vancomycin for Clostridium difificile-associated diarrhoea and colitis. Lancet 1983, 2:1043-1046.
  pubmed

• 19) Bartlett JG:Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339.
  pubmed

• 20) Tal S, Gurevich A, Guller V, Gurevich I, Berger D, Levi S:Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly. Scand J Infect Dis 2002, 34:594-597.
  pubmed

• 21) Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, Coll S, Oliver MI:Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993, 104:1133-1138.
  pubmed

• 22) Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG:The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992, 117:215-220.

• 23) Fong TL, Akriviadis EA, Runyon BA, Reynolds TB:Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. Hepatology 1989, 9:423-426.
  pubmed

• 24) Schlemper RJ, van der Werf SD, Biemond I, Lamers CB:Seroepidemiology of gastritis in Japanese and Dutch male employees with and without ulcer disease. Eur J Gastroenterol Hepatoｌ 1996, 8:33-39.
  pubmed

• 25) 日本ヘリコバクター学会ガイドライン作成委員会:H. pylori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2000, 2(Suppl):1-12.

• 26) Johnson CD:Antibiotic prophylaxis in severe acute pancreatitis. Br J Surg 1996, 83:883-884.
  pubmed

P.122 掲載の参考文献

• 1) 小林 裕, 春田常和, 大倉完悦:化膿性髄膜炎. 小児科MOOK. 金原出版, 東京, 1988, 53:19-29.

• 2) Tunkel AR, Scheld WM:Central nervous system infection. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p 173-221.

• 3) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 4) Reefhuis J, Honein MA, Whitney CG, Chamany S, Mann EA, Biemath KR, Broder K, Manning S, Avashia S, Victor M, Costa P, Devine O, Graham A, Boyle C:Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003, 349:435-445.

• 5) 斉藤 厚:髄膜炎, 脳膿瘍-成人. 抗菌薬使用のガイドライン (日本感染症学会, 日本化学療法学会編). 協和企画, 東京, 2005, p89-93.

• 6) Tunkel AR, Wispelwey B, Scheld WM:Bacterial meningitis:recent advances in pathophysiology and treatment. Ann Intern Med 1990, 112:610-623.
  pubmed

• 7) Quagliarello V, Scheld WM:Bacterial meningitis:pathogenesis, pathophysiology, and progress. N Engl J Med 1992, 327:864-872.
  pubmed

• 8) American Academy of Pediatrics:Pneumococcal infection. 2000 Red Book:Report of the Committee on Infectious Diseases, 25th ed. Pickering LK, ed. Elk Grove Village:American Academy of Pediatrics, 2000, p452-460.

• 9) Kaul A, Chandwani S:Dexamethasone in bacterial meningitis:to use or not to use? Indian J Pediatr 1996, 63:583-589.
  pubmed

• 10) American Academy of Pediatrics:Haemophilus influenzae infections. 2000 Red Book:Report of the Committee on Infectious Diseases, 25th ed. Pickering LK, ed. Elk Grove Village:American Academy of Pediatrics, 2000, p262-272.

• 11) Syrogiannopoulos GA, Lourida AN:Dexamethasone therapy for bacterial meningitis in children:2-versus 4-day regimen. J Infect Dig. 1994, 169:853-858.

• 12) De Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators:Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347:1549-1556.

• 13) Tunkel AR, Scheld WM:Corticosteroids for everyone with meningitis? N Engl J Med 2002, 347:1613-1615.
  pubmed

• 14) Kanegaye JT, Soliemanzadeh P, Bradley JS:Lumbar puncture in pediatric bacterial meningitis:defining the time interval for recovery of cerebrospinal fluid pathogens after parenteral antibiotic pretreatment. Pediatrics 2001, 108:1169-1174.
  pubmed

• 15) Kox LF, Kuijper S, Kolk AH:Early diagnosis of tuberculous meningitis by polymerase chain reaction. Neurology 1995, 45:2228-2232.
  pubmed

• 16) Nguyen LN, Kox LF, Pham LD, Kuijper S, Kolk AH:The potential contribution of the polymerasechain reaction to the diagnosis of tuberculous meningitis. Arch Neurol 1996, 53:771-776.

• 17) Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT:Prognosis of tuberculos meningitisin adults in the era of modern antituberculous chemotherapy. J Microbiol Immunol Infect 2002, 35:215-222.

• 18) Mahadevan B, Mahadevan S, Serane VT:Prognostic factors in childhood tuberculous meningitis. J Trop Pediatr 2002, 48:362-365.
  pubmed

• 19) American Academy of Pediatrics Committee on Infectious Diseases:Chemotherapy for tuberculosis in infants and children. Pediatrics 1992, 89:161-165.

P.129 掲載の参考文献

• 1) Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS:2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
  pubmed

• 2) Dykewicz CA, Kaplan JE:Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf

• 3) Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG:Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72:101-111.
  pubmed

• 4) EORTC International Antimicrobial Therapy Cooperative Project Group:Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86:668-672.

• 5) Freifeld A, Pizzo P:Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 1997, 16:140-146.
  pubmed

• 6) Aquino VM, Tkaczewski I, Buchanan GR:Early discharge of low-risk febrile neutropenic children and adolescents with cancer. Clin Infect Dis 1997, 25:74-78.
  pubmed

• 7) Joshi JH, Schimpff SC, Tenney JH, Newman KA, de Jongh CA:Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients? Am J Med 1984, 76:450- 457.

• 8) Centers for Disease Control and Prevention:Recommendations for preventing the spread of vancomycin resistance:recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). http://www.cdc.gov/mmwr/preview/mmwrhtml/00039349.htm

• 9) Elting LS, Bodey GP, Keefe BH:Septicemia and shock syndrome due to viridans streptococci:a case-control study of predisposing factors. Clin Infect Dis 1992, 14:1201-1207.
  pubmed

P.137 掲載の参考文献

• 1) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 2) Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC:Practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin Infect Dis 2005, 41:1373-1406.
  pubmed

• 3) 山本俊信, 鈴木幹三:嫌気性菌. 感染症診療実践マニュアル. 文光堂, 東京, 2002, p156-162.

• 4) 近藤 丘:外科系感染症(呼吸器外科領域). 抗菌薬使用のガイドライン(日本感染症学会, 日本化学療法学会・編). 協和企画, 東京, 2005, p163-164.

• 5) 田熊清継:外科系感染症(救急領域-外傷, 熱傷). 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p176-180.

• 6) 足立好司:外科系感染症(脳神経外科領域). 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p152-157.

• 7) 松下和彦:整形外科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p181-185.

P.153 掲載の参考文献

• 1) 岩田 敏:抗菌薬選択と使用の原則. 小児, 新生児. 抗菌薬使用のガイドライン(日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p15-24.

• 2) 吉田 勇, 杉森義一, 東山伊佐夫, 木村美司, 山野義則:各種抗菌薬に対する臨床分離株の感受性サーベイランス 2000年分離グラム陰性菌に対する抗菌力. 日化療会誌 2003, 51:209-232.

• 3) 中尾 亨:気道感染症. 小児感染症学. 金原出版, 東京, 1984, p441-516.

• 4) Gilbert DN, Moellering RC Jr, Eliopoulos, GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 33th ed. Hyde park:Antimicrobial Therapy, 2005.

• 5) Gal P, Reed MD:Antibacterial medications(antibiotics). Nelson textbook of pediatrics, 17th ed. Behrman RE, Kliegman RM, Jenson HB. eds. Pennsylvania:WB Saunders, 2004, p2485-2494.

• 6) Bannatyne RM, Cheung R:Susceptibility of Bordetella pertussis to cephalosporin derivatives and imipenem. Antimicrob Agents Chemother 1984, 26:604-605.
  pubmed

• 7) Hoppe JE, Botzenhart K:Susceptibility of Bordetella pertussis and Bordetella parapertussis to 24 antibiotics. Chemotherapy 1987, 33:250-254.
  pubmed

• 8) Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R:In vitro activity and stability against novel beta-lactalnases of investigational beta-lactams(cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds(cefotaxime, latamoxef and piperacillin). Infection 1991, 19(Suppl 5):S264-S275.

• 9) Long SS:Pertussis. Nelson textbook of pediatrics, 17th ed. Behrman RE, Kliegman RM, Jenson HB, eds. Pennsylvania:WB Saunders, 2004, p908-912.

• 10) 菅谷憲夫:インフルエンザ. 日本臨床 2003, 61(Suppl 2):135-140.

• 11) 砂川慶介:小児感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p141-145.

• 12) 森川嘉郎:化膿性髄膜炎の最近の治療. 小児感染免疫 2001, 13:177-187.

• 13) Elder JS:Urinary tract infections. Nelson textbook of pediatrics, 16th ed. Behrman RE, Kliegman RM, Jenson HB, eds. Pennsylvania:WB Saunders, 2000, p1621-1625.

• 14) Keren R, Chan E:Ameta-analysis of randomized, controlled trials comparing short-and long-course antibiotic therapy for urinary tract infections in children. Pediatrics 2002, 109:E70.

• 15) Michael M, Hodson EM, Craig JC, Martin S, Moyer VA:Short compared with standard duration of antibiotic treatment for urinary tract infection:a systematic review of randomised controlled trials. Arch Dis Child 2002, 87:118-123.
  pubmed

• 16) Ward TT, Jones SR:Genitourinary tract infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p493-540.

• 17) Cincinnati Children's Hospital Medical Center:Evidence based clinical practice guideline for patients 6 years of age or less with first time urinary tract infection (UTI). http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm

• 18) 平本龍吾:尿路感染症. 小児疾患の診断治療基準. (小児内科・小児外科編集委員会共・編), 東京医学社, 東京, 2001, p612-613.

• 19) 相楽裕子:内科系感染症(腸管感染症). 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p129-133,

• 20) French J, Camitta BM:The spleen. Nelson text book of pediatrics, 16th ed. Behrman RE, Kliegman R, Jenson HB, eds. Philadelphia:WB Saunders Company, 2000, p525-1527.

• 21) Hajjar FM, Pearson HA:Postsplenectomy sepsis. Gellis & Kagan's current pediatric therapy, 15th ed. Burg FD, Ingelfinger JR, Polin RA, Wald ER, eds. Philadelphia:WB Saunders Company, 1995, p320-321.

• 22) Shurin SB:Disorders of the spleen. Blood:Principles and practice of hematology, 1st ed. Handin RI, Lux SE, Stossel TP, eds. Philadelphia:Lippincott-Raven, 1995, p1359-1380.

• 23) 辻 芳郎:脾およびリンパ節の疾患. 小児科学. 医学書院, 東京, 1997, p1112-1118.

• 24) 鈴木賢二:耳鼻咽喉科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p204-207.

• 25) 渡辺晋一:皮膚科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p146-151.

• 26) 遠藤廣子:市中感染と耐性菌-急性気道感染症と中耳炎. 小児感染免疫 2003, 15:59-67.

• 27) 大石正夫:眼科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編), 協和企画, 東京, 2005, p208-212.

P.165 掲載の参考文献

• 1) Schaeffer AJ:Infections of the urinary tract. Campbell's urology, 7th ed. Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Philadelphia:WB Saunders Company, 1998, p533-614.

• 2) Sobel JD, Kaye D:Urinary tract infections. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p875-905.

• 3) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde park:Antimicrobial Therapy, 2005.

• 4) Hooton TM:Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001, 17:259- 268.

• 5) Ward TT, Jones SR:Genitourinary tract infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Pem RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p493-540.

• 6) 国立大学医学部附属病院感染対策協議会:尿路感染防止, 尿道留置カテーテル管理. 病院感染対策ガイドライン. 平成15年8月版. 2003, p52-58.

• 7) Warren JW:Nosocomial urinary tract infections. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p3370-3381.

• 8) Fan-Havard P, O'Donovan C, Smith SM, Oh J, Bamberger M, Eng RH:Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995, 21:960-965.

• 9) Meares EM Jr:Prostatitis and related disorders. Campbell's urology, 7th ed. Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Philadelphia:WB Saunders Company, 1998, p615-630.

P.180 掲載の参考文献

• 1) Gibbs RS:Microbiology of the female genital tract. Am J Obstet Gynecol 1987, 156:491-495.
  pubmed

• 2) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 3) Saez-Llorens X, McCracken GH Jr:Clinical pharmacology of antibacterial agents. Infectious diseases of the fetus and newborn infant, 5th ed. Remington JS, Klein JO, eds. Philadelphia:WB Saunders, 2001, p 1419-1466.

• 4) Little BB:Pharmacokinetics during pregnancy:evidence-based maternal dose formation. Obstet Gynecol 1999, 93:858-868.
  pubmed

• 5) Ito S:Drug therapy for breast-feeding women. N Engl J Med 2000, 343:118-126.
  pubmed

• 6) Rivera-Calimlim L:Drugs in breast milk. Drug Ther(NY) 1973, 7:59-63.

• 7) Scott A, Forsyth S:Breast feeding and antibiotics. Mod Midwife 1996, 6:14-16.
  pubmed

• 8) Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK:Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983, 74:14-22.
  pubmed

• 9) Brook I:Aerobic and anaerobic microbiology of Bartholin's abscess. Surg Gynecol Obstet 1989, 169:32-34.

• 10) Spiegel CA, Amsel R, Holmes KK:Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J Clin Microbiol 1983, 18:170-177.
  pubmed

• 11) Gulmezoglu AM:Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev 2000:CD 000218.

• 12) Centers for Disease Control and Prevention:Sexually transmitted diseases treatment guidelines 2002. Morb Mort Wkly Rep 2002, 51:1-78.

• 13) 日本産科婦人科学会:産婦人科医のための社会保険ABC, 改訂2版. メジカルビュー社, 東京, 2000.

• 14) 日本産婦人科医会:感染とパートナーシップ, 研修ノート69. 日本産婦人科医会, 東京, 2002.

• 15) Lossick JG, Kent HL:Trichomoniasis:trends in diagnosis and management. Am J Obstet Gynecol 1991, 165:1217-1222.
  pubmed

• 16) Sobel JD, Nyirjesy P, Brown W:Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001, 33:1341-1346.
  pubmed

• 17) オーストラリア治療ガイドライン委員会:抗生物質治療ガイドライン. 医薬ビジネスセンター, 松原, 1999.

• 18) Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD:A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients whithout neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331:1325-1330.

• 19) Sobel JD:Candidal vulvovaginitis. Clin Obstet Gynecol 1993, 36:153-165.
  pubmed

• 20) Kontoyiannis D, Lewis RE:Antifungal dmg resistance of pathogenic fungi. Lancet 2002, 359:1135-1144.

• 21) Goldenberg RL, Hauth JC, Andrews WW:Intrauterine infection and preterm delivery. N Engl J Med 2000, 342:1500-1507.
  pubmed

• 22) 岡田弘二, 保田仁介:産婦人科領域感染症, 感染症の現況と対策. 日医雑誌 1993, 110(臨時増刊号):137-140.

• 23) 厚生省・日本医師会:骨盤内感染症-特に子宮内感染症, 付属器炎(卵管炎), 抗菌薬療法, 診療のてびき. 日医雑誌 1994, 112(付録4):52-54.

• 24) 河野一郎:婦人科感染症, 婦人科疾患の診断・治療・管理. 日産婦誌 2003, 55:N104- N109.

• 25) 野口昌良:婦人科感染症 STD, 婦人科疾患の診断・治療・管理. 日産婦誌 2003, 55:N109-N117.

• 26) Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE:Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334:1362-1366.
  pubmed

• 27) McCormack WM:Pelvic Inflammatory Disease. N Engl J Med 1994, 330:115-119.
  pubmed

• 28) Barbosa-Cesnik C, Schwartz K, Foxman B:Lactation mastitis. JAMA 2003, 289:1609-1612.
  pubmed

• 29) Schwarz RJ, Shrestha R:Needle aspiration of breast abscesses. Am J Surg 2001, 182:117-119.
  pubmed

• 30) Gibbs RS, Duff P:Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol 1991, 164:1317-1326.
  pubmed

• 31) American College of Obstetricians and Gynecologists:ACOG educational bulletin. Antimicrobial therapy for obstetric patients. Int J Gynaecol Obstet 1998, 61:299-308.
  pubmed

• 32) Newton ER:Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993, 36:795-808.
  pubmed

• 33) 松田清治:抗菌薬の体内動態. 周産期医学 1998, 28:1415-1419.

• 34) Duff P:Antibiotic selection in obstetrics:making cost-effective choices. Clin Obstet Gynecol 2002, 45:59-72.
  pubmed

• 35) Berenson AB, Hammill HA, Martens MG, Faro S:Bacteriologic findings of post-cesarean endometritis in adolescents. Obstet Gynecol 1990, 75:627-629.
  pubmed

• 36) Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDV, Clark SL:Williams Obstetrics, 20th ed. Stamford:Appleton & Lange, 1997.

• 37) Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, Baker CJ:Group B streptococcal colonization and serotype-specific immunity in pregnant women in delivery. Obstet Gynecol 2000, 96:498-503.

• 38) Centers for Disease Control and Prevention:Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. Morb Mort Wkly Rep. 2002, 51(RR-11):1-22.

• 39) Hamadeh MA, Glassroth J:Tuberculosis and pregnancy. Chest 1992, 101:1114-1120.
  pubmed

• 40) Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thomton G:Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994, 149:1359-1374.

• 41) Davidson PT:Managing tuberculosis during pregnancy. Lancet 1995, 346:199-200.
  pubmed

• 42) Shin S, Guerra D, Rich M, Seung KJ, Mukherjee J, Joseph K, Hurtado R, Alcantara F, Bayona J, Bonilla C, Farmer P, Furin J:Treatment of multi-resistant tuberculosis during pregnancy:a report of 7 cases. Clin Infect Dis 2003, 36:996-1003.

P.190 掲載の参考文献

• 1) 鈴木賢二:耳鼻咽喉科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p204-207.

• 2) 大石正夫:眼科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p208-212.

• 3) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 4) Bemard HD:感染性眼内炎の治療:EVSにおける成績. 眼科手術 1998, 11:179-190.

• 5) 臼井正彦:レボフロキサシン点眼液の手術前無菌法試験. あたらしい眼科 1997, 14:953-956.
  Medical*Online

• 6) Gimbel HV, Sun R, DeBroff BM, Yang HM:Anterior chamber fluid cultures following phacoemulsification and posterior chamber lens implantation. Ophthalmic Surg Lasers 1996, 27:121-126.
  pubmed

• 7) Feys J, Salvanet-Bouccara A, Emond JP, Dublanchet A:Vancomycin prophylaxis and intraocular contamination during cataract surgery. J Cataract Refract Surg 1997, 23:894-897.
  pubmed

P.204 掲載の参考文献

• 1) 渡辺晋一:皮膚科感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p146-151.

• 2) 毛利 忍:皮膚・軟部組織感染症. 感染症診療実践マニュアル. 文光堂, 東京, 2002, p68-71.

• 3) 神崎寛子, 荒田次郎:皮膚科領域感染症. 抗生物質療法ガイド. 文光堂, 東京, 1996, p324-328.

• 4) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde park:Antimicrobial Therapy, 2005.

• 5) 笠井達也:皮膚・口腔カンジダ症. 今日の治療指針 1994. 医学書院, 東京, 1994, p150-154.

• 6) 西山千秋:白癬. 今日の治療指針 1994. 医学書院, 東京, 1994, p622-623.

• 7) Wood MJ:The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996, 37:209-222.
  pubmed

• 8) 横田邦信, 柴 孝也:糖尿病と日和見感染, 新世紀の感染症学(下). 日本臨床 2003, 61(Suppl 3):149-152.

• 9) 高橋 久:クロストリジウム以外の嫌気性蜂巣炎. 領域別感染症シリーズ23 感染症症候群I. 日本臨床社, 大阪, 1999, p587-588.

• 10) 清水可方, 大江健二:劇症型A群溶連菌(人喰いバクテリア)感染症. 領域別感染症シリーズ23 感染症症候群I. 日本臨床社, 大阪, 1999, p115-118.

• 11) 中尾 亨:リンパ節腫脹を来す感染症. 小児感染症学. 金原出版, 東京, 1984, p997-1010.

• 12) 大屋恵子, 木村光明, 山出晶子, 鶴田 悟, 吉田隆実:入院治療を要した重症アトピー性皮膚炎患者の特徴. 日児誌 2001, 105:81-87.

• 13) 厚生省健康政策局指導課:院内感染対策Q&A. ヘルス出版, 東京, 1997.

• 14) 齋藤 厚, 砂川慶介, 炭山嘉伸, 中島光好, 池澤善郎, 比嘉太, 佐々木緊, 矢野裕二:日本化学療法学会皮内反応検討特別部会報告書. 日化療会誌 2003, 51:497-506.

• 15) 斉藤 厚, 砂川慶介, 中島光好, 炭山嘉伸, 池澤善郎, 比嘉太, 佐々木緊, 矢野裕二:抗菌薬投与に関連するアナフィラキシー対策のガイドライン. (社団法人日本化学療法学会臨床試験委員会皮肉反応検討特別部会・編),2004年版

P.214 掲載の参考文献

• 1) Crossley KB, Peterson PK:Infections in the elderly. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. New York:Elsevier Churchill Livingstone, 2004, p3164-3169.

• 2) Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH:Gatifloxacin and the elderly:phar nacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003, 52:435-440.

• 3) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人院内肺炎診療の基本的考え方. 日本呼吸器学会, 東京, 2002, p60-68.

• 4) Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ:Practice guidelines for themanagement of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31:347-382.

• 5) Medina-Walpole AM, Katz PR:Nursing-home acquired pneumonia. J Am Geriatr Soc 1999, 47:1005-1015.
  pubmed

• 6) Kasper DL:Infections due to mixed anaerobic organisms. Harrison's principles of internal medicine, 15th ed. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. New York:McGraw-Hill, 2001, p1011-11017.

• 7) Marik PE:Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001, 344:665-671.
  pubmed

• 8) Naughton BJ, Mylotte JM:Treatment guideline for nursing home-acquired pneumonia based on community practice. J Am Geriatr Soc 2000, 48:82-88.
  pubmed

• 9) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 10) 国立大学医学部附属病院感染対策協議会:ウイルス感染防止対策. 病院感染対策ガイドライン, 平成15年8月版. 2003, p36-41.

• 11) Lopez FA, Sanders CV:Skin and soft-tissue infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p97-126.

• 12) Durand ML:Eye infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p222-250.

P.218 掲載の参考文献

• 1) Centers for Disease Control and Prevention:Recommendations for preventing transmission of infections among chronic hemodialysis patients. http://www.cdc.gov/mmwr/PDF/rr/rr5005.pdf

• 2) Bartley J:First case of VRSA identified in Michigan. Infect Control Hosp Epidemiol 2002, 23:480.
  pubmed

• 3) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

P.229 掲載の参考文献

• 1) Centers for Disease Control and Prevention:Sexually transmitted diseases treatment guidelines 2002. Morb Mort Wkly Rep 2002, 51:1-78.

• 2) 日本性感染症学会:性感染症診断・治療ガイドライン. 日性感染症会誌 1999, 10:8-38.

• 3) 日本性感染症学会:性感染症診断・治療ガイドライン. 日性感染症会誌 2000, 11:10-47.

• 4) 日本産婦人科医会:感染とパートナシップ, 研修ノート69. 日本産婦人科医会, 東京, 2002.

• 5) 野口昌良:婦人科感染症. 日産婦誌 2003, 55:N104-N117.

• 6) 日本産科婦人科学会:産婦人科医のための社会保険ABC, 改訂2版. メジカルビュー社, 東京, 2003.

• 7) 松田静治, 八神善昭:性感染症, 今日的課題と最新の診断・治療, 図説産婦人科 View 5. メジカルビュー社, 東京, 1994.

• 8) Houpt ER, Rein M:Sexually transmitted diseases and obstetric and gynecologic infections. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p541-587.

• 9) オーストラリア治療ガイドライン委員会:抗生物質治療ガイドライン. 医薬ビジネスセンター, 松原, 1999.

• 10) Adair CD, Gunter M, Stovall TG, Mcelroy G, Veille JC, Ernest JM:Chtamydia in pregnancy:a randomized trial of azithromycine and erythromicin. Obstet Gynecol 1998, 91:165-168.

• 11) Fox KK, Moran J:Control of Neisseria gonorrhoeae infection in the United State. CDC External Consultation on Gonorrhea Control. 2001:1-18.

• 12) 日本性感染症学会:淋菌, 性感染症診断・治療ガイドライン. 日性感染症会誌 1999, 10:17-23.

• 13) Duff P:Antibiotic selection in obstetrics:making cost-effective choices. Clin Obstet Gynecol 2002, 45:59-72.
  pubmed

• 14) 小島弘敬:淋菌感染症. 感染症の診断・治療ガイドライン. (感染症の診断・治療研究会・編), 日医誌 1999, 122(臨時増刊):238-239.

• 15) 日本産婦人科医会:淋菌感染症. 感染とパートナーシップ, 研修ノート69. 東京, 2002, p38-40.

• 16) Handsfield HH, McComlack WM, Hoor EW III, Douglas JM Jr, Covino JM, Verdon MS, Reichart CA, Ehret JM, and Gonorrhea Treatment Study Group:Acomparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. N Engl J Med 1991, 325:1337-1341.

• 17) Dicker LW, Mosure DJ, Berman SM, Levine WC:Gonorrhea prevalence and coinfection with Chlamydia in women in the United States, 2000. Sex Transm Dis 2003, 30:472-476.
  pubmed

• 18) 高田道夫:性行為感染症(STD) , 梅毒. 産婦人科領域感染症. 医薬ジャーナル, 大阪, 1988, p105-109.

• 19) 日本性感染症学会:梅毒, 性感染症診断・治療ガイドライン. 日性感染症会誌 1999, 10:14-16.

• 20) 津上久弥:梅毒の治療. 皮膚科MOOK4 STD(性行為感染症). 金原出版, 東京, 1986, p79-89.

• 21) 淵 勲:妊婦梅毒. 皮膚科MOOK4 STD(性行為感染症). 金原出版, 東京, 1986, p90-96.

• 22) Romanowski B, Sutherland R, Fick GH, Mooney D, Love EJ:Serologic response to treatment of infectious syphilis. Ann Intern Med 1991, 114:1005-1009.
  pubmed

• 23) ACOG educational bulletin:Antimicrobial therapy for obstetric patients. Int J Gynaecol Obstet 1998, 61:299-308.
  pubmed

• 24) Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berly S, Corey L:Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med 1987, 317:1246-1251.

• 25) Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A, Ashley R, Watts DH, Berry S, Herd M, Corey L:The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997, 337:509-515.
  pubmed

• 26) Sperling RS, Sapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O, Sullivan MJ, van Dyke RB, Jimenez E, Rouzioux CR, Flym PM, Sullivan JL:Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency vims type 1 from mother to infant. Pediatric AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med 1996, 335:1621-1629.

• 27) HIV母子感染予防の臨床的研究班:平成13年度HIV母子感染予防対策マニュアル, 第2版. 2002.

• 28) Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O, Sullivan MJ, van Dyke R, Bey M, Shearer W, Jacobson RL, Jimenez EJ, O'Neill E, Bazin B, Delfraissy J-F, Culname M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J:Reduction of maternal-infant transmission of immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.

• 29) Landesman SH, Kalish LA, Bums DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L, Tuomala R:for the Women and Infants Transmission Study:Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996, 334:1617-1623.

• 30) The International Perinatal HIV Group:Mede of delivery and vertical transmission of HIV-1:a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999, 340:977-987.

P.246 掲載の参考文献

• 1) Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA:Principles of appropriate antibiotic use for treatment of acute bronchitis:background. Ann Intern Med 2001, 134:521-529.
  pubmed

• 2) Kaiser L, Lew D, Hirschel B, Auckenthaler R, Morabia A, Heald A, Benedict P, Terrier F, Wunderli W, Matter L, Germann D, Voegeli J, Stalder H:Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 1996, 347:1507-1510.
  pubmed

• 3) Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y:Azithromycin for acute bronchitis:a randomised, double-blind, controlled trial. Lancet 2002, 359:1648-1654.
  pubmed

• 4) Cooper RJ, Hoffman JR, Bartlett JG, Besser RE, Gonzales R, Hickner JM, Sande MA:Principles of appropriate antibiotic use for acute pharyngitis in adults:background. Ann Intern Med 2001, 134:509-517.
  pubmed

• 5) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人気道感染症診療の基本的考え方. 日本呼吸器学会, 東京, 2003.

• 6) Snow V, Mottur-Pilson C, Gonzales R:Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001, 134:518-520.
  pubmed

• 7) Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA:Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults:background, specific aims, and methods. Ann Intern Med 2001, 134:479-486.
  pubmed

• 8) 三笠桂一, 澤木政好, 国松幹和, 浜田 薫, 成田亘啓, 三上理一郎, 松本一郎, 川名林治:かぜ症候群に続発する細菌性呼吸器感染症の検討. 感染症誌 1987, 61:858-863.

• 9) Saint S, Bent S, Vittinghoff E, Grady D:Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995, 273:957-960.
  pubmed

• 10) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 11) Chole RA, Faddis BT:Anatomical evidence of microbial biofilms in tonsillar tissues:apossible mechanisms to explain chronicity. Arch Otolaryngol Head Neck Surg 2003, 129:626-628.

• 12) Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA:Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis:background. Ann Intern Med 2001, 134:521-529.
  pubmed

• 13) Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B:Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 2001, 32:1691-1697.
  pubmed

• 14) Read RC:Orocervical and esophageal infection. Infectious disease. Armstrong D, Cohen J, eds. London:Mosby, 1999, p33. 1-33.

• 15) Rorber M:Teeth and periodontium. The Merk manual, 17th ed. Beers MH, Berkow R, eds. Whitehouse Station:Merck Research Laboratories, 1999, p759-769.

• 16) 佐久間孝久:こどもの口内咽頭所見, こどもの皮疹・口内咽頭所見チェックガイド. 総合診療ブックス. (絹巻 宏, 横田俊一郎・編) , 医学書院, 東京, 2000, p146-154.

• 17) Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R:Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996, 129:761-764.
  pubmed

• 18) Hauben M, Amsden GW:The association of erythromycin and infantile hypertrophic pyloric stenosis:causal or coincidental? Drug Saf 2002, 25:929-942.
  pubmed

• 19) Sorensen HT, Skriver MV, Pedersen L, Larsen H, Ebbesen F, Schonheyder HC:Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003, 35:104-106.
  pubmed

• 20) Maeda S, Yamada Y, Nakamura H, Maeda T:Efficacy of antibiotics against influenza-like illness in an influenza epidemic. Pediatr Int 1999, 41:274-276.

• 21) Ninomiya K, Fukui T, Imai T, Matsui M, Matsuoka K:Effect of macrolides on duration and resolution of symptoms and complication of pneumonia in children with influenza. J Nippon Med Sch 2002, 69:53-57

• 22) Treanor JJ, Hall BC:Influenza and infections of the trachea, bronchi, and bronchioles. A practical approach to infectious diseases, 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins, 2003, p282-285.

• 23) Sethi S:Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics 2002, 57:56-61

• 24) 宮下修行, 深野浩史, 松島敏春:市中肺炎外来治療の抗菌薬選択とその用い方. Medical Practice 2002, 19:1877-1881.

• 25) Miyashita N, Fukano H, Niki Y, Matsushima T, Okimoto N:Etiology of community-acquired pneumonia requiring hospitalization in Japan. Chest 2001, 119:1295-1296.
  pubmed

• 26) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人市中肺炎診療ガイドライン. 日本呼吸器学会, 東京, 2005.

• 27) Miyashita N, Fukano H, Okimoto N, Hara H, Yoshida K, Niki Y, Matsushima T:Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults. Chest 2002, 121:1776-1781

• 28) 青木信樹:呼吸器感染症-肺炎. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2001, p106-121.

• 29) Niederman MS, Malldell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Manie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL:Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Care Med 2001, 163:1730-1754.

• 30) Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ:Practice guidelines for the management of community-acquired pneumoniae in adults. Clin Infect Dis 2000, 31:347-382.

• 31) Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C:Infectious Diseases Society of America:Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003, 37:1405-1433.

• 32) 成田光生, 中山雅之, 山田 諭, 岡崎則男, 佐々木次雄:肺炎マイコプラズマ感染症における臨床的クリンダマイシン耐性について. 臨床小児医学 2000, 48:123-127.

• 33) Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki Y, Arakawa Y, Sasaki T:Characteristics of macrolide-resistant mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001, 45:617-620.
  pubmed

• 34) Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK:Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
  pubmed

• 35) Centers for Disease Control and Prevention:Prevention of pneumococcal disease:recommendations of the Advisory Committee on Immunization Practices(ACIP). 1997 Morb Mort Wkly Rep Recomm Rep 1997, 46:1-24.

• 36) Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force:Guidelines for the prevention and treatment of infection in patients with an absent dysfunctional spleen. BMJ 1996, 312:430-434,
  pubmed

• 37) 相楽裕子:腸管感染症. 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p129-133.

• 38) Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Griffin PM, DuPont H, Sack RB, Tarr P, Neill M, Nachamkin I, Reller LB, Osterholm MT, Bennish ML, Pickering LK:Infectious Diseases Society of America:Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32:331-350.

• 39) Graman PS, Betts RF:Gastrointestinal and intraabdominal infections. A practical approach to infectious diseases. 5th ed. Betts RF, Chapman SW, Penn RL, eds. Philadelphia:Lippincott Williams & Wilkins 2003, p403-438.

• 40) Dowell SF, Schwartz B:Resistant pneumococci:protecting Patients through judicious use of antibiotics. Am Fam Physician 1997, 55:1647-1654.
  pubmed

[4] 抗菌薬の予防的投与と局所投与

P.264 掲載の参考文献

• 1) 日本感染症学会, 日本化学療法学会:抗菌薬使用のガイドライン. 協和企画, 東京, 2005.

• 2) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde Park:Antimicrobial Therapy, 2005.

• 3) Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G:Prevention of bacterial endocarditis-recommendations by the American Heart Association. JAMA 1997, 277:1794-1801.
  pubmed

• 4) Strom BL, Abmtyn E, Berlin JA, Kinman JL, Feldman RS, Stolley PD, Levison ME, Korzeniowski OM, Kaye D:Dental and cardiac risk factors for infective endocarditis:a population-based, casecontrol study. Ann Intern Med 1998, 129:761-769.

• 5) Seymour RA, Lowry R, Whitworth JM, Martin MV:Infective endocarditis, dentistry and antibiotic prophylaxis;time for a rethink?Br Dent J 2000, 189:610-616.
  pubmed

• 6) Stollerman GH:Rheumatic fever. Lancet 1997, 349:935-942.
  pubmed

• 7) American Thoracic Society and Centers for Disease Control and Prevention:Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000, 161:S221-S247.
  pubmed

• 8) 森 亨:結核の積極的疫学調査:接触者健診の事後措置. 保健所における結核対策強化の手引きとその解説. 財団法人結核予防会, 東京, 2000, p34-35.

• 9) Juckett G:Prevention and treatment of traveler's diarrhea. Am Fam Physician 1999, 60:119-136.
  pubmed

• 10) DuPont HL, Ericsson CD:Prevention and treatment of travelers' diarrhea. New Engl J Med 1993, 328:1821-1827.

• 11) Hilton E, Kolakowski P, Singer C, Smith M:Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 1997, 4:41-43.
  pubmed

• 12) Centers for Disease Control and Prevention:Control and prevention of serogroup C meningococcal disease:evaluation and management of suspected outbreaks:recommendations of the Advisory Committee on Immunization Practices(ACIP) . Morb Mort Wkly Rep 1997, 46:13-21. http://www.cdc.gov/mmwr/PDF/RR/RR4605.pdf

• 13) Hooton TM:Recurrent urinary tract infection in women. Int J Antimicrob Agents 2001, 17:259- 268.

• 14) Stamm WE, Hooton TM:Management of urinary tract infections in adults. N Engl J Med 1993, 329:1328-1334.
  pubmed

• 15) Sobel JD, Kaye D:Urinary tract infections. Principles and practice of infectious diseases, 6th ed. Mandell GL, Bennett JE, Doloin R, eds, New York:Elsevier Churchill Livingstone, 2004, p875- 905.

• 16) Pfau A, Sacks T, Engelstein D:Recurrent urinary tract infections in premenopausal women:prophylaxis based on an understanding the pathogenesis. J Urol 1983, 129:1153-1157.

• 17) Pfau A, Sacks TG:Effective prophylaxis of recurrent urinary tract infections in premenopausa I women by postcoital administration of cephalexin. J Urol 1989, 142:1276-1278.

• 18) Stapleton A, Latham RH, Johnson C, Stamm WE:Postcoital antimicrobial prophylaxis for recurrent urillary tract infection:a randomized, double-blind, placebo-controlled trial. JAMA 1990, 264:703-706.
  pubmed

• 19) Brumfitt W, Hamilton-Miller JM:Efficacy and safety profile of long-term nitrofurantoin in urinary infection:18 years' experience. J Antimicrob Chemother 1998, 42:363-371.
  pubmed

• 20) Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E:Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients:ameta-analysis. Clin Infect Dis 1996, 23:795-805.

• 21) Hughes WT, Ammstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep IL, Young LS:2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.

• 22) Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, The Canadian Fluconazole Prophylaxis Study Group:Randomized placebo-controlled trial of fluconazole for neutropenic cancer patients:benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999, 28:331-340.

• 23) Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C, Matsuyama T, Takezako N, Miwa A, Kem W, Kami M, Akiyama H, Hirai H, Togawa A:Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. Cancer 2000, 89:1611-1625.

• 24) Hughes WT, Rivera GK, Schell MJ, Thomton D, Lott L:Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987, 316:1627-1632.

• 25) Hasur H:Prevention and treatment of pneumocystis pneumonia. N Engl J Med 1992, 327:1853-1860.

• 26) Santamauro JT:Pneumocystis carinii pneumonia in patients with and without HIV infection. Comp Ther 2002, 28:96-108.

• 27) Dykewicz CA, Jaffe HW, Kaplan JE:Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000, 6:659-734.

• 28) Bowben RA, Myers JD:Infection complicating bone marrow transplantation. Clinical approach to infection in the compromised host, 3rd ed. Rubin RH, Young LS, eds. New York:Plenum Medical Book, 1994, p601-628.

• 29) Slavin MA, Osbome B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Myers JD, Bowden RA:Efficacy and safety of fiuconazole prophylaxis for fungal infections after marrow transplantation-aprospective, randomized, double-blind study. J Infect Dis 1995, 171:1545- 1552.

• 30) Link H, Vohringer H-F, Wingen F, Bragas B, Schwardt A, Ehninger G:Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow transplant 1993, 11:403-406.
  pubmed

• 31) Centers for Disease Control and Prevention:Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U. S. Public Health Service and the Infectious Diseases Society of America. Morb Mort Wkly Rep 2002, 51:1-52. http://www.cdc.gov/mmwr/PDF/RR/RR5108.pdf

• 32) Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force:Guidelines for the prevention and treatment of infection in patients with an absent dysfunctional spleen. BMJ 1996, 312:430-434.
  pubmed

P.278 掲載の参考文献

• 1) Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR:Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999, 20:250-278.
  pubmed

• 2) Nichols RL:Surgical antibiotic prophylaxis. Med Clin North Am 1995, 79:509-522.
  pubmed

• 3) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed, Hyde Park:Antimicrobial Therapy, 2005.

• 4) 国立大学医学部附属病院感染対策協議会:手術部位感染防止対策. 病院感染対策ガイドライン, 平成15年8月版. 2003, p69-76.

• 5) Rovera F, Imperatori A, Militello P, Morri A, Antonini C, Dionigi G, Dominioni L:Infections in 346consecutive video-assisted thoracoscopic procedures. Surg Infect 2003, 4:45-51.
  pubmed

• 6) Lippert H, Gastinger J:Antimicrobial prophylaxis in laparoscopic and conventional cholecystectomy. Chemotherapy 1998, 44:355-363.
  pubmed

• 7) Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twonbley J, French PP, Herwaldt LA:the Mupirocin and the Risk of Staphylococcus aureus Sudy Team:Intranasal mupirocin to prevent postoperative of Staphylococcus aureus infections. N Engl J Med 2002, 346:1871-1877.

• 8) 足立好司:外科系感染症(脳神経外科領域) . 抗菌薬使用のガイドライン. (日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p152-157.

• 9) 松下和彦:整形外科感染症. 抗菌薬使用のガイドライン(日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p181-185.

• 10) Gibbs RS:Microbiology of the female genital tract. Am J Obstet Gynecol 1987, 156:491-495.
  pubmed

• 11) Brooker DC, Savage JE, Twiggs LB, Adcock LL, Prem KA, Sanders CC:Infectious morbidity in gynecologic cancer. Am J Obstet Gynecol 1987, 156:513-520.
  pubmed

• 12) Mittendorf R, Aronson MP, Berry RE, Williams MA, Kupelnik B, Klickstein A, Herbst AL, Chalmers TC:Avoiding serious infections associated with abdominal hysterectomy:a meta- analysis of antibiotic prophylaxis. Am J Obstet Gynecol 1993, 169:1119-1124.

• 13) ACOG educational bulletin:Antibiotics and gynecologic infection. Int J Gynaecol Obstet 1997, 58:333-340.
  pubmed

• 14) ACOG educational bulletin:Antimicrobial therapy for gynecologic infections. Int J Gynaecol Obstet 1992, 38:131-139.

• 15) Ross ER:Prophylaxis against tetanus. American college of surgeons trauma programs, 1995. http://www.facs.org/dept/trauma/publications/traumaon.html

• 16) Osmon DR:Antimicrobial prophylaxis in adults. Mayo Clin Proc 2000, 75:98-109.
  pubmed

P.288 掲載の参考文献

• 1) American Academy of Pediatrics:Pertussis. 2000 Red Book:Report of the Committee on Infectious Diseases, 25th ed. Pickering LK, ed. Elk Grove Village:American Academy of Pediatrics, 2000, p435-448.

• 2) American Academy of Pediatrics:Meningococcal infections. 2000 Red Book:Report of the Committee on Infectious Dieases, 25th ed. Pickering LK, ed. Elk Grove Village:American Academy of Pediatrics, 2000, p396-401.

• 3) American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newbom:Revised guidelines for prevention of early-onset group B streptococcal(GBS) infection. Pediatrics 1997, 99:489-496.

• 4) Bisno AL:Acute pharyngitis. N Engl J Med 2001, 344:205-211.
  pubmed

• 5) Arroll B, Kenealy T:The use of antibiotics versus placebo in the common cold(Cochrane Review) . The Cochrane Library, Issue 3, Oxford, 1999.

• 6) Kerr JR, Preston NW:Current pharmacotherapy of pertussis. Expert Opin Phaimacother 2001, 2:1275-1282.
  pubmed

• 7) Aoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R:Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 1996, 129:761-764.
  pubmed

• 8) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Sande MA:The Sanford guide to antimicrobial therapy 2005, 35th ed. Hyde park:Antimicrobial Therapy, 2005.

• 9) 国立大学医学部附属病院感染対策協議会:ウイルス感染防止対策. 病院感染対策ガイドライン(第2版) , 平成15年8月版, 2003, p36-41.

• 10) 庵原俊昭:ムンプスワクチン暴露後接種(緊急接種)の有効性. 日本醫事新報, 東京, 2003, 4136:94-95.

• 11) American Academy of Pediatrics:Varicella-Zoster infections. 2000 Red Book:Report of the Committee on Infectious Diseases, 25th ed. Pickering LK, ed. Elk Grove Village:American Academy of Pediatrics, 2000, p624-638.

• 12) 須賀定雄, 古川哲史, 浅野喜造, 矢崎雄彦, 尾崎隆男:水痘潜伏期の経口アシクロビル投与量と疾患軽症化の検討. 臨床とウイルス 1994, 22:304-307.

• 13) Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Ozaki T, Yamada A, Imanishi J:Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics 1993, 92:219-222.
  pubmed

• 14) Centers for Disease Control and Prevention:Prevention of pneumococcal disease:recommendations of the Advisory Committee on Immunization Practices(ACIP). Morb Mort Wkly Rep Recomm Rep 1997, 46:1-24.

• 15) Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM:Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998, 44:760-765.

• 16) Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM:Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma 2002, 53:1037-1042.
  pubmed

• 17) 菅谷憲夫:インフルエンザ. 小児科 2002, 43:1849-1854.

• 18) Centers for Disease Control and Prevention:Prevention and control of influenza:recommendations of the Advisory Committee on Immunization Practices(ACIP) . Morb Mort Wkly Rep 1997, 46:1- 25.

• 19) 新庄正宜, 佐藤清二, 菅谷憲夫, 三田村敬子, 武内可尚, 小崎健次郎, 高橋孝雄:小児病棟における, インフルエンザ接触者へのオセルタミビル予防内服効果. 感染症誌 2004, 78:262-269.

• 20) 森 亨・編:結核の積極的疫学調査:接触者健診の事後措置. 保健所における結核対策強化の手引きとその解説, 財団法人結核予防会, 東京, 2000, p34-35.

• 21) Dajani AS, Taubert KA, Wilson W, Bolger AF, B ayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G Jr:Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997, 277:1794-1801.

• 22) Schrpder H, Agger KE, Rosthoj S, Carlsen NT, Schmiegelow K:Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia. Dan Med Bull 2001, 48:275-277.

• 23) Kadoya A, Okada J, Iikuni Y, Kondo H:Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996, 23:1186-1188.
  pubmed

• 24) Wolff LJ:Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Use of prophylactic antibiotics. Am J Pediatr Hematol Oncol 1984, 6:267-276.

• 25) Centers for Disease Control and Prevention:Prevention of pneumococcal disease:recommendations of the Advisory Committee on Immunization Practices(ACIP) . 1997 Morb Mort Wkly Rep Recomm Rep 1997, 46:1-24.

• 26) Davidson RN, Wall RA:Prevention and management of infections in patients without spleen. Clin Microbiol Infect 2001, 7:657-660.
  pubmed

• 27) French J, Camitta BM:The spleen. Nelson text book of pediatrics, 16th ed. Behrman RE, Kliegman R, Jenson HB, eds. Philadelphia:WB Saunders Company 2000, p 1525-1527.

• 28) Hajjar FM, Pearson HA:Postsplenectomy sepsis. Gellis & Kagan's current pediatric therapy, 15th ed. Burg FD, Ingelfinger JR, Polin RA, Wald ER, eds. Philadelphia:WB Saunders Company, 1995, p320-321.

• 29) Shurin SB:Disorders of the spleen. Blood:Principles and practice of hematology, 1st ed. Handin RI, Lux SE, Stossel TP, eds. Philadelphia:Lippincott-Raven, 1995, p 1359-1380.

• 30) 辻 芳郎:脾およびリンパ節の疾患. 小児科学. 医学書院. 東京, 1997, p1112-1118.

P.298 掲載の参考文献

• 1) Centers for Disease Control and Prevention:Guideline for the prevention of intravascular catheter-related infections. http://www.cdc.gov/mmwr/PDF/rr/rr5110.pdf

• 2) 松下和彦:整形外科感染症. 抗菌薬使用のガイドライン(日本感染症学会, 日本化学療法学会・編) , 協和企画, 東京, 2005, p181-185.

• 3) American Thoracic Society:Infectious Diseases Society of America:Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.

• 4) Favero, MS:Disinfection, sterilization, and preservation. Chemical disinfection of medical and surgical materials, 4th ed. Block SS, ed. Philadelphia:Lea & Febiger, 1993, P617-641.

• 5) Centers for Disease Control and Prevention:Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf

• 6) Doebbeling BN, Breneman DL, Neu HC, Aly R, Yangco BG, Holley HP Jr, Marsh RJ, Pfaller MA, McGowan JE Jr, Scully BE, Reagan DR, Wenzel RP, the Mupirocin Collaborative Study Group:Elimination of Staphylococcus aureus nasal carriage in health care workers:analysis of six clinical trials with mupirocin calcium ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993, 17:466-474.

• 7) Centers for Disease Control and Prevention:Guideline for prevention of surgical site infection. http://www.cdc.gov/ncidod/hip/SSI/SSI.pdf

• 8) Perl TM, Cullen JJ, Wenzel RP, Zimmeman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA, the Mupirocin and the Risk of Staphylococcus aureus Study Team:Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002, 346:1871-1877.

[5] 国内外の診療ガイドラインの活用と抗菌薬療法

P.317 掲載の参考文献

• 1) Hayward RS, Wilson MS, Tunis SR, Bass EB, Guyatt G:Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence- Based Medicine Working Group. JAMA 1995, 274:570-574.

• 2) Wilson MC, Hayward RS, Tunis SR, Bass EB, Guyatt G:Users' guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. JAMA 1995, 274: 1630-1632.

• 3) 急性胆道炎の診断ガイドラインの作成出版委員会:急性胆管炎・胆嚢炎の診療ガイドライン. 医学図書出版, 東京, 2005.

• 4) 深在性真菌症のガイドライン作成委員会:深在性真菌症の診断・治療ガイドライン2007. 協和企画, 東京, 2007.

• 5) 日本造血細胞移植学会:造血細胞移植ガイドライン-移植後早期の感染管理. http://www.jshct.com/guide_pdf/2000.pdf

• 6) Centers for Disease Control and Prevention:Targeted tuberculin testing and treatment of latent tuberculosis infection. http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/rr4906a1.htm

• 7) Centers for Disease Control and Prevention:Recommendations for preventing the spread of vancomycin resistance. http://www.cdc.gov/mmwr/preview/mmwrhtml/00039349.htm

• 8) Centers for Disease Control and Prevention:Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. http://www.cdc.gov/mmwr/PDF/rr/rr4910.pdf

• 9) Centers for Disease Control and Prevention:Guideline for the prevention of surgical site infection. http://www.cdc.gov/ncidod/hip/SSI/SSI.pdf

• 10) Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ:Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000, 31:347-382.
  pubmed

• 11) Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL:Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Care Med 2001, 163, 1730-1754.

• 12) 日本呼吸器学会市中肺炎診療ガイドライン作成委員会:「呼吸器感染症に関するガイドライン」成人市中肺炎診療ガイドライン, 日本呼吸器学会, 東京, 2005.

• 13) Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS:2002 Guidelines for the use of antimicrobial agents in the neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
  pubmed